Development of a novel type of recombinant anti-SARS-CoV-2 vaccine

The DNA-FACE™ concept of construction of ‘artificial’, concatemeric protein with a vaccine functionality has been used to construct an anti-SARS-CoV-2 vaccine. The co-polymerization type construct contains multiple copies of various epitopes clusters, derived from the SARS-CoV-2 virus proteins. The clusters were selected using a proprietary method developed in BioVentures Institute Ltd.. Currently, this novel type of anti-SARS-CoV-2 vaccine undergoes initial animal trials. It needs to be emphasized that the DNA-FACE™ concept used to develop anti-SARS-CoV-2 vaccine also applies to essentially all types of microbial pathogens as well as to cancer cells.